研究领域

Cancer Treatment and Detection

Role of oncogenic signalling pathways in enhancing the survival and proliferation of cancer cells Genetic effectors of melanoma resistance to cancer therapies Impact of MAPK inhibitors on immune regulatory pathways in melanoma Utility of circulating tumour DNA and RNA as prognostic tool

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Carlino, M. S., Todd, J. R., Gowrishankar, K., Mijatov, B., Pupo, G. M., Fung, C., Snoyman, S., Hersey, P., Long, G. V., Kefford, R. F., and Rizos, H. (2014) Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 8, 544-554 Gray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J., Lee, J. H., Scolyer, R. A., Siew, K., Lomma, C., Cooper, A., Khattak, M. A., Meniawy, T. M., Long, G. V., Carlino, M. S., Millward, M., and Ziman, M. (2015) Circulating tumour DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget (in press) Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., Howle, J., Hayward, N. K., Johansson, P., Scolyer, R. A., Kefford, R. F., and Rizos, H. (2014) Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun5, 5694 Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., Howle, J., Saw, R., Thompson, J. F., Kefford, R. F., Scolyer, R. A., and Long, G. V. (2014) BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Res20, 1965-1977